Posted on 01/22/2002 10:44:57 AM PST by rdavis84
LANSING, Mich. (AP) - In 1998, the buyers of the only U.S. laboratory making the anthrax vaccine thought they had a can't-miss deal.
The aging state-owned lab in Michigan needed millions in renovations on top of the $24 million purchase price. But the Pentagon already had announced it would require all 2.4 million American military personnel to take a series of six shots of the vaccine, and turning the lab into a profitable enterprise seemed childishly easy.
Four years later, Lansing-based BioPort Corp. has yet to ship a single dose of the vaccine to the Pentagon.
Unable to pass inspections by the Food and Drug Administration, BioPort has intermittently produced the vaccine but has not been able to release it.
Now, the company appears to be on the verge of finally winning FDA approval to begin shipments, possibly as early as this month.
"It's clearly a very positive story for the company," said BioPort spokeswoman Kim Brennen Root.
A laboratory in Washington state that puts the vaccine into vials still needs FDA approval, and the vaccine still must be tested for purity, potency and sterility before batches will be released by the FDA.
The vaccine was held up by contamination, inadequate record-keeping and unapproved procedures at the laboratory.
"I'm glad it took four years. That stuff needed to be done right," said Rep. Mike Rogers, R-Mich., whose district includes BioPort.
BioPort is under contract to the Pentagon to supply 4.6 million doses for $53.5 million.
Pressure to get the lab approved has grown since U.S. troops began heading overseas in the war on terrorism and since last fall's anthrax outbreak killed five people on the East Coast. Because of the standstill at Bioport, the Pentagon stockpile of the vaccine is dwindling.
Over the past four years, BioPort has received at least $16.8 million from the Pentagon to renovate and expand the lab. The Pentagon also agreed in 1999 to more than double the per-dose payment, from $4.36 to $10.36.
Considering who owns BioPort, it was something of a surprise that the project did not turn out to be as easy as the new owners expected.
BioPort's chief executive and major investor, Fuad El-Hibri, is a former director of a British maker of an anthrax vaccine. A major shareholder in BioPort is retired Adm. William J. Crowe, former chairman of the Joint Chiefs of Staff, who brought his experience dealing with the Pentagon to the fledgling company. Also, the former director of the state-owned lab is BioPort's chief operating officer.
Even so, BioPort continued to fail FDA inspections. It contracted with Hollister-Stier Laboratories in Spokane, Wash., to put the vaccine into vials when its own packaging procedures could not make the grade.
BioPort also was cited for not following approved manufacturing procedures, for contamination problems and for inaccurate or incomplete testing documentation. Several lots of the vaccine failed sterility tests.
The company also was criticized for not investigating reactions to the vaccine that were different from those listed on the package insert. Among other things, an Army cook died in 2000 from a form of anemia and other complications. BioPort denies the vaccine caused the death.
Amid the anthrax scare and the war on terrorism, some have questioned whether the FDA is being pushed to overlook problems at BioPort.
"The FDA is under tremendous pressure to cave on this," Lingg Brewer, a former state lawmaker, said last fall.
Health and Human Services Secretary Tommy Thompson said in October that the FDA would give the laboratory close scrutiny and that science, not politics, would decide when it got the OK.
"I can assure you nobody is pressuring FDA to approve this," he said.
Even if the FDA gives BioPort the green light, more problems lie ahead.
Some military personnel say the vaccine they were given in the late 1990s made them ill, leading to congressional inquiries and lawsuits. Opponents to the vaccine have asked the FDA to declare all stockpiles adulterated and to revoke BioPort's license.
BioPort officials have said the vaccine is safe, and the Pentagon said severe side effects happen only about once per 200,000 doses.
Also, questions remain over the vaccine's effectiveness against the inhaled form of anthrax, which has killed five people in the recent outbreak. BioPort and the Pentagon said the vaccine protects against the inhaled form.
But even the Pentagon says a better vaccine is needed, one that does not require a series of six shots over 18 months and has fewer side effects. BioPort wants to work on such a vaccine, but so do others.
---
I wonder who put the pressure on the FDA.
BioPort officials have said the vaccine is safe, and the Pentagon said severe side effects happen only about once per 200,000 doses."
The money has and will continue to change hands in this contest. And the foregone Loser is the G.I.
Almost works out to be a "plan", doesn't it?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.